• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

左西孟旦作为杜氏肌营养不良症患者急性心力衰竭的抢救治疗药物

Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.

作者信息

Sumanaru Dorin, Josseran Loic, Essid Aben, Mbieleu Blaise, Haegy Isabelle, Bergounioux Jean

机构信息

Pediatric Intensive Care Unit, Hôpital Raymond-Poincaré, APHP, 92380, Garches, France.

Epidemiology Department, Hôpital Raymond-Poincaré, APHP, 92380, Garches, France.

出版信息

Pediatr Cardiol. 2019 Mar;40(3):668-670. doi: 10.1007/s00246-019-02072-9. Epub 2019 Feb 22.

DOI:10.1007/s00246-019-02072-9
PMID:30796500
Abstract

The longer survival of patients with Duchenne muscular dystrophy due to advances in clinical care has increased the incidence of Duchenne muscular dystrophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.

摘要

由于临床护理的进步,杜氏肌营养不良症患者的生存期延长,这增加了杜氏肌营养不良症相关心肌病的发病率,这是在生命的第三个十年中几乎一致出现的特征。一名26岁的杜氏肌营养不良症患者因肺炎引发了严重的急性心力衰竭。左西孟旦在改善心脏功能方面有效。

相似文献

1
Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.左西孟旦作为杜氏肌营养不良症患者急性心力衰竭的抢救治疗药物
Pediatr Cardiol. 2019 Mar;40(3):668-670. doi: 10.1007/s00246-019-02072-9. Epub 2019 Feb 22.
2
Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application.左西孟旦作为治疗脓毒症诱导型心肌病的新力量:作用机制与临床应用
J Int Med Res. 2019 May;47(5):1817-1828. doi: 10.1177/0300060519837103. Epub 2019 Apr 8.
3
Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy.贝克尔肌营养不良相关心肌病:药物治疗效果良好。
J Heart Lung Transplant. 2002 Apr;21(4):496-8. doi: 10.1016/s1053-2498(01)00316-3.
4
Advances in the diagnosis and management of cardiomyopathy in Duchenne muscular dystrophy.杜氏肌营养不良症中心肌病的诊断和管理进展。
Neuromuscul Disord. 2018 Sep;28(9):711-716. doi: 10.1016/j.nmd.2018.06.014. Epub 2018 Jul 6.
5
Intermittent inotrope infusion for end stage heart failure in Duchenne muscular dystrophy.间歇性输注正性肌力药物治疗杜氏肌营养不良症终末期心力衰竭
Neuromuscul Disord. 2008 Dec;18(12):1005-6; author reply 1006. doi: 10.1016/j.nmd.2008.09.002. Epub 2008 Oct 25.
6
[Efficacy and safety of levosimendan in elderly patients with severe heart failure].左西孟旦治疗老年重症心力衰竭患者的疗效与安全性
Zhonghua Nei Ke Za Zhi. 2020 Jun 1;59(6):433-438. doi: 10.3760/cma.j.cn112138-20190827-00587.
7
Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.左西孟旦用于急性和晚期心力衰竭:临床数据库评估及其治疗应用评价
J Cardiovasc Pharmacol. 2018 Mar;71(3):129-136. doi: 10.1097/FJC.0000000000000533.
8
Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy.门诊持续输注正性肌力药物作为杜氏肌营养不良症心力衰竭治疗的辅助手段。
Neuromuscul Disord. 2006 Nov;16(11):745-8. doi: 10.1016/j.nmd.2006.07.021. Epub 2006 Sep 26.
9
Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.左西孟旦在急性和晚期心力衰竭中的应用:剂量和治疗应用的专家观点。
Cardiovasc Drugs Ther. 2018 Dec;32(6):617-624. doi: 10.1007/s10557-018-6838-2.
10
High effectiveness of repeated levosimendan cycles in a patient with advanced heart failure.晚期心力衰竭患者重复使用左西孟旦周期的高效性。
Med Clin (Barc). 2017 Sep 8;149(5):226. doi: 10.1016/j.medcli.2017.04.035. Epub 2017 Jun 19.

引用本文的文献

1
Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update.杜氏肌营养不良症中的早期心脏功能障碍:一例报告及文献综述
Int J Mol Sci. 2025 Feb 16;26(4):1685. doi: 10.3390/ijms26041685.

本文引用的文献

1
Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.左西孟旦无负荷剂量对终末期心力衰竭患者收缩和舒张功能的影响。
Cardiol J. 2011;18(5):532-7. doi: 10.5603/cj.2011.0009.
2
Clinical pharmacology of levosimendan.左西孟旦的临床药理学
Clin Pharmacokinet. 2007;46(7):535-52. doi: 10.2165/00003088-200746070-00001.
3
Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
左西孟旦对缺血性或扩张型心肌病所致失代偿性晚期心力衰竭患者室性心律失常及预后自主神经指标的影响。
Am J Cardiol. 2006 Dec 15;98(12):1641-5. doi: 10.1016/j.amjcard.2006.07.043. Epub 2006 Oct 25.
4
Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.左西孟旦对脓毒症性心肌抑制时全身和局部血流动力学的影响。
Intensive Care Med. 2005 May;31(5):638-44. doi: 10.1007/s00134-005-2619-z. Epub 2005 Apr 6.
5
The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.钙增敏剂左西孟旦与心律失常:心力衰竭治疗研究安全数据库分析
Scand Cardiovasc J. 2004 May;38(2):80-4. doi: 10.1080/14017430410025783.
6
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.重度低心排血量心力衰竭患者中静脉注射左西孟旦与多巴酚丁胺疗效及安全性比较(LIDO研究):一项随机双盲试验
Lancet. 2002 Jul 20;360(9328):196-202. doi: 10.1016/s0140-6736(02)09455-2.
7
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.新型正性肌力药物左西孟旦对衰竭人心肌等长张力和钙循环的影响。
Circulation. 1998 Nov 17;98(20):2141-7. doi: 10.1161/01.cir.98.20.2141.
8
The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy.杜氏肌营养不良症中心肌病的发病率及演变过程。
Int J Cardiol. 1990 Mar;26(3):271-7. doi: 10.1016/0167-5273(90)90082-g.